Equity Details
Price & Market Data
Price: $1.11
Daily Change: -$0.11 / 9.91%
Daily Range: $1.11 - $1.21
Market Cap: $13,371,103
Daily Volume: 16,915
Performance Metrics
1 Week: 20.00%
1 Month: 11.76%
3 Months: 14.18%
6 Months: -38.04%
1 Year: -47.87%
YTD: -17.39%
About CytoMed Therapeutics Limited (GDTC)
Comprehensive financial data on CytoMed Therapeutics Limited (GDTC). Trading at 1.11, it has a daily change of -$0.11 / 9.91%. Market cap: 13,371,103. Review its performance from the last week to the last year.
Company Details
Employees: 42
Sector: Health technology
Industry: Biotechnology
Country: Singapore
Details
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company also has Business & Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.
